Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,885 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06067841RecruitingPhase 1
New drug for advanced prostate cancer
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT07416552RecruitingPhase 1
Study of CEA-PRIT 2.0 for advanced colorectal cancer
This trial tests an experimental drug called CEA-PRIT 2.0 in people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
Omaha, NebraskaAges 18 years+ - NCT07545811RecruitingPhase 1
JANX014 for Advanced Prostate Cancer
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
St Louis, MissouriAges 18 years+ - NCT06767449Recruiting
Zolbetuximab for Claudin18.2 positive stomach cancer
This trial is for people with advanced stomach cancer that has a specific protein called Claudin18.2 and is HER2-negative. It tests whether continuing zolbetuximab—a drug that targets this protein—can help control the cancer.
SeoulAges 19 years+ - NCT06761287Recruiting
Choosing surgery after chemo for advanced rectal cancer
This study looks at patients with advanced rectal cancer who had treatment (chemotherapy or radiation) before surgery. They want to see if it's safe to avoid surgery in those who had a good response to initial treatment.
BrusselsAges 18 years+ - NCT06638307RecruitingPhase 1
Study of new drug MEN2312 for advanced breast cancer with specific genetic changes
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
Springdale, ArkansasAges 18 years+ - NCT04573231RecruitingPhase 2
PET scan using PSMA for AR-positive metastatic breast cancer
This Phase 2 study looks at using a special PET/CT scan tracer called PSMA to find signals in metastatic breast cancer that has high androgen receptor (AR) activity. It may help researchers better measure and target this type of cancer.
Madison, WisconsinAges 18 years+ - NCT06598800RecruitingPhase 1
Study of BG-T187 alone or with other drugs for advanced solid tumors
This trial tests a new treatment, BG-T187, given alone or with other medicines for people with advanced solid tumors that have spread or cannot be removed. It is for those who have already tried other treatments.
Hackensack, New JerseyAges 18 years+ - NCT07427394RecruitingPhase 2
Camizestrant and atirmociclib for advanced breast cancer
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
St Louis, MissouriAges 18 years+ - NCT07493512RecruitingPhase 1
Study of xaluritamig for metastatic prostate cancer
This trial tests a new drug called xaluritamig for men with metastatic prostate cancer that is resistant to hormone therapy. It is designed for those who have already tried certain hormone pills and one type of chemotherapy, and aims to see if the drug can shrink tumors or slow cancer growth.
Denver, ColoradoAges 18 years+ - NCT06367075RecruitingPhase 2
Cadonilimab plus adriamycin for advanced soft tissue sarcoma
This trial tests a combination of two drugs—cadonilimab (a type of immunotherapy) and adriamycin (chemotherapy)—for adults with advanced soft tissue sarcoma that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow their growth.
Wuhan, HubeiAges 18–75 - NCT06258408RecruitingPhase 1
BB102 for advanced solid tumors that have not responded to treatment
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
Guangzhou, GuangdongAges 18–78 - NCT04219137Recruiting
MOCHA study of blood and biopsy features in stomach tumors
This study looks at the “molecular” features (biologic characteristics) of gastroesophageal cancer from tissue samples. It may help doctors better understand which cancers are best matched to treatment plans and future therapies.
Toronto, OntarioAges 18 years+ - NCT07749586RecruitingPhase 1/Phase 2
Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
Huntersville, North CarolinaAges 18 years+ - NCT07751042RecruitingPhase 1/Phase 2
Study of STX-003 with and without pembrolizumab for advanced solid tumors
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT05886920RecruitingPhase 1/Phase 2
Study drug for advanced cancers with specific MAPK changes
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Detroit, MichiganAges 18 years+ - NCT07414836RecruitingPhase 1
First test of new drug BG-C0979 for advanced solid tumors
This study tests a new drug called BG-C0979 for advanced solid tumors that have not responded to standard treatments. It may be given alone or with other therapies to see if it can shrink tumors or slow cancer growth.
St Louis, MissouriAges 18 years+ - NCT06941818Enrolling by invitationPhase 1
TIL therapy for advanced melanoma
This trial tests a new cell therapy made from your own tumor-fighting cells (TILs) for advanced melanoma that hasn't responded to other treatments. It aims to shrink tumors by re-infusing these boosted cells back into your body.
BeijingAges 18–75 - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06992583RecruitingPhase 1
CAR-T cell therapy for advanced CEA-positive lung cancer
This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.
Nanjing, JiangsuAges 18 years+ - NCT06914661Enrolling by invitation
DS8201 for metastatic breast cancer: a real-world study
This trial looks at the safety and effectiveness of DS8201 in people with metastatic breast cancer (cancer that has spread to other parts of the body). Doctors will review medical records to see how well the drug works and how safe it is.
Changchun, JilinAges 18–100 - NCT06840821RecruitingPhase 1/Phase 2
Testing MB0151 for cancers with somatostatin receptors
This trial tests a new drug, MB0151, for adults with advanced solid tumors that have somatostatin receptors and have not responded to standard treatments. It aims to see if MB0151 is safe and can shrink tumors.
Jinan, ShandongAges 18 years+ - NCT06841159RecruitingPhase 2
Personalized radiation plus immunotherapy and chemo for metastatic colorectal cancer
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
ShanghaiAges 18–75 - NCT06859762RecruitingPhase 1
YL217 for advanced solid tumors (first-in-human)
This study tests a new drug, YL217, for people with advanced solid tumors. It is a first-in-human trial, meaning this drug has not been tested in people before, and aims to see if it is safe and how well it works.
Phoenix, ArizonaAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,885 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.